KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Return on Sales (2017 - 2025)

Sarepta Therapeutics has reported Return on Sales over the past 13 years, most recently at 0.8% for Q4 2025.

  • Quarterly results put Return on Sales at 0.8% for Q4 2025, up 56.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (down 16.0% YoY), and the annual figure for FY2025 was 0.04%, down 16.0%.
  • Return on Sales for Q4 2025 was 0.8% at Sarepta Therapeutics, up from 0.45% in the prior quarter.
  • Over the last five years, Return on Sales for SRPT hit a ceiling of 1.24% in Q4 2021 and a floor of 23.48% in Q1 2023.
  • Median Return on Sales over the past 5 years was 0.19% (2021), compared with a mean of 2.34%.
  • Biggest five-year swings in Return on Sales: crashed -2298bps in 2023 and later soared 2357bps in 2024.
  • Sarepta Therapeutics' Return on Sales stood at 1.24% in 2021, then tumbled by -85bps to 0.18% in 2022, then skyrocketed by 66bps to 0.3% in 2023, then dropped by -20bps to 0.24% in 2024, then soared by 230bps to 0.8% in 2025.
  • The last three reported values for Return on Sales were 0.8% (Q4 2025), 0.45% (Q3 2025), and 0.32% (Q2 2025) per Business Quant data.